These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11286542)

  • 21. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome.
    Hellmich B; Ciaglo A; Schatz H; Coakley G
    Ann Rheum Dis; 2004 Jul; 63(7):862-6. PubMed ID: 15194585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF).
    Akasheh M; Eastwood D; Vesole DH
    Bone Marrow Transplant; 2003 Jan; 31(2):113-6. PubMed ID: 12621492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.
    Reali E; Canter D; Zeytin H; Schlom J; Greiner JW
    Vaccine; 2005 Apr; 23(22):2909-21. PubMed ID: 15780740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
    Lissoni P; Mengo S; Bucovec R; Brivio F; Fumagalli L; Tancini G; Gardani GS
    In Vivo; 2003; 17(1):73-5. PubMed ID: 12655794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
    Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
    Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi W; Chatzissavvidis I; Valek V
    Eur J Surg Oncol; 2001 Nov; 27(7):652-61. PubMed ID: 11669594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2.
    Uemura Y; Kobayashi M; Nakata H; Kubota T; Saito T; Bandobashi K; Taguchi H
    Oncol Rep; 2007 Apr; 17(4):955-61. PubMed ID: 17342342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CMRF-56 immunoselected blood dendritic cell preparations activated with GM-CSF induce potent antimyeloma cytotoxic T-cell responses.
    Freeman JL; Vari F; Hart DN
    J Immunother; 2007 Oct; 30(7):740-8. PubMed ID: 17893566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.
    Barrio MM; de Motta PT; Kaplan J; von Euw EM; Bravo AI; Chacón RD; Mordoh J
    J Immunother; 2006; 29(4):444-54. PubMed ID: 16799340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
    Schwaab T; Tretter C; Gibson JJ; Cole BF; Schned AR; Harris R; Wallen EM; Fisher JL; Waugh MG; Truman D; Stempkowski LM; Crosby NA; Heaney J; Ernstoff MS
    J Urol; 2004 Mar; 171(3):1036-42. PubMed ID: 14767265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of neutralising antibodies restricts the use of human granulocyte/macrophage colony stimulating factor for vaccine studies in rhesus macaques.
    Eisenblätter M; Stahl-Hennig C; Kuate S; Stolte N; Jasny E; Hahn H; Pope M; Tenner-Racz K; Racz P; Steinman RM; Uberla K; Ignatius R
    Vaccine; 2004 Sep; 22(25-26):3295-302. PubMed ID: 15308352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
    Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
    Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of GM-CSF immune accessory effects in tumor-bearing mice by direct gene immunization.
    Dou J; Hong X; Zhao F; Wang J; Chen J; Chen G
    Immunol Invest; 2006; 35(2):227-37. PubMed ID: 16698679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
    Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
    Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.